Folate Receptor Alpha (FRα) is overexpressed in a range of solid tumors with limited expression in normal tissues, hence an attractive target for an antibody-drug conjugate (ADC). 

PRO1184 is comprised of a human monoclonal antibody that selectively binds human FRα, a novel cleavable hydrophilic linker, and a topoisomerase 1 inhibitor payload, exatecan. 

PRO1184 demonstrates broad antitumor activity with a promising safety profile in preclinical models.